A Phase 3, multicentre, open label, randomized, parallel group Study to Compare Efficacy,Safety and Immunogenicity of Biosimilar Recombinant Insulin Aspart Mix 30 (Manufactured by BioGenomics Limited) with NovoMix 30®(Manufactured by Novo Nordisk), in Diabetes Mellitus patients
A double-blind, randomized, single-center, two treatment, four period, two sequence, replicate crossover, euglycemic clamp study to demonstrate equivalence in the pharmacokinetic and pharmacodynamic properties of Insulin Glargine 100 IU/mL of BioGenomics Limited and Lantus® (Insulin Glargine 100 IU/mL of Sanofi-Aventis) in healthy, adult, human male subjects under fasting condition
A Randomized, Double Blind, Single Center, Two Treatment, Two-Period, TwoSequence, Crossover, Euglycemic clamp study to demonstrate equivalence in thePharmacokinetic and Pharmacodynamic properties of Insulin Aspart Mix 30 ofBioGenomics Limited and NovoMix® 30 of Novo Nordisk in healthy, adult, humanmale subjects under fasting condition.
100 Clinical Results associated with Biogenomics Ltd.
0 Patents (Medical) associated with Biogenomics Ltd.
100 Deals associated with Biogenomics Ltd.
100 Translational Medicine associated with Biogenomics Ltd.